- Fresenius Kabi has entered into a strategic development agreement with TQ Therapeutics to license proprietary cell selection technology for cell and gene therapy manufacturing.
- The agreement aims to support scalable, efficient production of high-purity T cells using an automated processing system.
Fresenius Kabi has entered into a strategic development agreement with TQ Therapeutics, under which Fresenius Kabi has secured an exclusive licence to develop, manufacture, and distribute products incorporating TQ Therapeutics’ proprietary cell selection technology. The agreement is intended to improve scalability and efficiency in cell and gene therapy manufacturing.
Under the terms of the collaboration, TQ Therapeutics’ affinity- and column-based cell isolation technology will be integrated into Fresenius Kabi’s Cue® Cell Processing System. The combined platform is designed to isolate T cells from whole blood and apheresis products in less than two hours, supporting faster and more consistent cell therapy manufacturing workflows.
Fresenius Kabi said the integration aims to enable the rapid and reproducible production of high-purity T cells, helping therapy developers streamline manufacturing processes and potentially accelerate delivery of treatments to patients. The collaboration aligns with the company’s broader activities in cell therapies and contract manufacturing operations.
“By integrating TQ Therapeutics’ novel selection technology into our Cue system, our aim is to improve manufacturing success and scalability—key steps toward supporting the advancement of cell and gene therapies.”
Saurabh Bhasin, Head of Portfolio, Cell Therapies & Contract Manufacturing Operations at Fresenius Kabi
TQ Therapeutics stated that the partnership will support development of ultra-short, extracorporeal cell and gene therapy processes that could be applied closer to the point of care. The company said the agreement is intended to broaden access to its technology and support wider adoption of cell therapies as programmes progress towards clinical use.
